N/A N=20 Tactile Breast Imaging Sensor for Tumor Malignancy Characterization
Breast Cancer
Primary: Size Error in Millimeters — 0 milimeters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=70 Benefit of a Diagnostic MRI in Case of Pathological Nipple Discharge With Normal Mammography / Ultrasound
Breast Cancer
Primary: The Negative Predictive Value (PVV) of MRI
N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
N/A N=23 A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers
Breast Cancer
Primary: The Distance Measured by Pathology From the Tumor Edge to the Center of the Ink Spots, as Marked by the Black Inked Pins. — 1.7 cm
Phase 4 N=21 Symptom Management After Breast Cancer Surgery
Neuropathic Pain · Postmastectomy Pain
Primary: Change in Pain Intensity on an 11-point Scale From Baseline to 12 Weeks — 4.0 units on a scale
Phase 2 N=60 Feasibility Study of Intraoperative Imaging in Breast Cancer
Breast Cancer
Primary: (Phase A Only) Selection of Dose of LUM015 to be Used in Future Breast Trials — 2.1; 4.7; 4.2 Ratio
Phase 2 N=234 Intraoperative Detection of Residual Cancer in Breast Cancer
Breast Cancer
Primary: Collect Data to Refine and Verify the Tumor Detection Algorithm. — 11.3 Percentage
N/A N=45 ARFI, VisR and DDAI Ultrasound for Improving Discrimination of Malignant and Unresponsive Breast Cancer
Breast Cancer
Primary: Correlation of Peak Displacement (PD) for Detecting Malignancy — 4.5803; 8.628 microns — p=0.2988
N/A N=670 Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment
Breast Cancer Related Lymphedema · Covid19
Primary: COVID-19 Vaccination on Contralateral vs Ipsilateral Arm — 432; 435; 331; 122 Participants
N/A N=1 Prospective Evaluation of a Surgical Solution for Breast Cancer-Associated Lymphedema
Lymphedema · Edema
Primary: Change in Limb Volume — -15; -202 mL
N/A N=35 CairnSurgical Breast Cancer Locator (BCL) Post-Market Study
Breast Cancer
Primary: Positive Margin Rate — 2 Participants
N/A N=2,978 Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue
Breast Carcinoma
Primary: Rate of Detection of Invasive Cancers — 9; 14 Participants
N/A N=13 Upper Extremity Lymphatic Mapping for Breast Cancer Patients
Breast Cancer · Axillary Lymph Node Dissection
Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants
Phase 3 N=406 Investigation of Novel Surgical Imaging for Tumor Excision
Breast Cancer
Primary: Percentage of Patients Who Had Residual Cancer Found in at Least One LUM Imaging System Guided Shave Among All Patients. — 7.6 percentage of participants
N/A N=6,266 Assessment of Periodic Screening of Women With Denser Breast Using WBUS and DBT
Breast Cancer
Primary: Cancer Yield Per 1,000 — 5.0; 6.3; 4.9; 5.9 Cancer yield per 1,000 — p=0.005
N/A N=29 Magnetic Seed Localisation of Breast Cancers
Breast Cancer
Primary: Migration of Sentimark Device — 100 percentage of Magseed migrating >10mm
N/A N=39 Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer
Breast Cancer
Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants
Phase 3 N=163 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
N/A N=1,681 Ultrasound Elastography of Breast Lesions
Breast Neoplasms
Primary: Estimates of Effect of Selectively Upgrading BIRADS Category 3 and Downgrading BIRADS 4a Masses Based on SWE Features. Overall Specificity and Sensitivity of BI-RADS…
N/A N=36,444 Surveillance Imaging Modalities for Breast Cancer Assessment
Breast Cancer
Primary: Number of Breast Cancers Detected — 279; 27 cancers detected
N/A N=20 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
Breast Cancer · Ductal Carcinoma in Situ
Primary: Ipsilateral Recurrence Rate — 0 participants
N/A N=298 Diagnostic US for Reduction of Benign Breast Biopsies Using US-guided Optical Tomography
Breast Biopsy
Primary: Impact of US-guided DOT on the Potential Reduction of Benign Biopsies as Measured by Comparing the Reads With a Non- Suspicious Assessment of Conventional Imaging (CI)…
Phase 2 N=37 Stellate Ganglion Block (SGB) For Women for Breast Cancer
Hot Flushes · Hot Flashes
Primary: Change in Number of Night Sweats From Baseline to 6 Months After Intervention. — 5.46; 10.09 night sweats/month
Phase 4 N=219 Quantitative Subharmonic Breast Imaging
Breast Cancer
Primary: Number of Breast Cancer Lesions Characterized as Malignant or Benign With 3D SHI, Harmonic Imaging (HI) or Power Doppler Imaging (PDI) — 69; 24; 126; 58 lesions
Phase 2 N=61 Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
Breast Cancer Female
Primary: Measure Ki67 Index in Highly Hormone-dependent Breast Cancers vs. Those That Are Not — 7; 6; 40 Participants
N/A N=97 Study of Prone Accelerated Breast And Nodal IMRT
Lymphedema
Primary: Number of Participants With Acute Toxicity > Grade 2 (Skin Toxicity Grade 3 or Above) Occurring Within 60 Days After First Day of Treatment — 4 Participants
N/A N=934 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases
Breast Cancer
Primary: 5-year Disease-Free Survival — 84.4; 87.8 percentage of participants — p=0.004
N/A N=21 Radiofrequency of Breast Cancers in Non Surgical Patients
Breast Cancer
Primary: Number of Participants With Disease Recurrence One Year After the Intervention. — 1 Participants
N/A N=20 Positron Emission Mammography (PEM) Biopsy Accessory for the Diagnosis of Breast Cancer
Breast Cancer
Primary: Feasibility That Breast Biopsy Can be Performed Using PEM and Stereo Navigator Software After Diagnostic PEM on the Same Day. — 22; 21; 6; 26 Breast Lesions
Phase 2 N=72 Protocol for Women at Increased Risk of Developing Breast Cancer
Breast Cancer
Primary: Change in Percent of Breast Epithelial Cells Staining Positive for Ki-67 — -1.2; -2.0 percentage of cells staining positive — p=0.71